Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 tadalafil trial in ambulatory boys with Duchenne muscular dystrophy
NL-OMON40274Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tadalafil in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in 6-minute walk distance. Started May 2014; status: active, not recruiting.
02
Drugs
tadalafil
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON40274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40274.